Sugi Predict

Sugi Predict / Targets / NOTUM

NOTUM

Palmitoleoyl-protein carboxylesterase NOTUM · Q6P988 · NOTUM on Sugi Atlas →

145,542 patent compounds predicted against NOTUM, 67,420 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL182023 SCHEMBL182023 1.00 20/20
SCHEMBL76794 SCHEMBL76794 0.64 16/20
SCHEMBL9555 SCHEMBL9555 1.00 15/20
SCHEMBL75570 SCHEMBL75570 0.63 14/20
SCHEMBL68594 SCHEMBL68594 0.72 12/20
SCHEMBL69432 SCHEMBL69432 0.60 8/20
SCHEMBL167133 SCHEMBL167133 0.47 8/20
SCHEMBL13291 SCHEMBL13291 0.44 8/20
SCHEMBL46855 SCHEMBL46855 0.42 8/20
SCHEMBL8428 SCHEMBL8428 0.47 7/20
SCHEMBL14562 SCHEMBL14562 0.45 7/20
SCHEMBL82595 SCHEMBL82595 0.64 6/20
SCHEMBL184324 SCHEMBL184324 0.52 6/20
SCHEMBL112926 SCHEMBL112926 0.51 6/20
Clopirac Clopirac (SCHEMBL24768) 0.61 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL111600) 0.60 5/20
SCHEMBL157086 SCHEMBL157086 0.60 5/20
SCHEMBL115085 SCHEMBL115085 0.52 5/20
SCHEMBL40676 SCHEMBL40676 0.41 5/20
SCHEMBL58303 SCHEMBL58303 0.40 5/20

Clinical trials — most relevant to NOTUM by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL) PHASE4COMPLETED
Randomized Controlled Trial of Silymarin in Asthma PHASE2/PHASE3WITHDRAWN
NEO100 and High-Grade Meningioma PHASE2RECRUITING
Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis PHASE2UNKNOWN
A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder PHASE2COMPLETED
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis PHASE2COMPLETED
A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR) PHASE2COMPLETED
Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo PHASE2UNKNOWN
Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency PHASE2ACTIVE_NOT_RECRUITING
A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy PHASE1WITHDRAWN
Alcohol Inhibits Drug Metabolism by Carboxylesterases PHASE1COMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Targeting zDHHC Enzymes to Counteract Alzheimer's Disease nanNOT_YET_RECRUITING
Improving Metabolism With HDL Cholesterol nanCOMPLETED
Istmin Levels in Laparoscopik Sleeve Gastrectomy nanCOMPLETED
Androgens and NAFLD Longitudinal Cohort Study nanRECRUITING
Use of MCT Oil for Enhancement of Weight Loss in Obese Patients nanCOMPLETED
Human Requirements for the Nutrient Choline nanCOMPLETED
Sex Hormones and Blood PCSK9 Levels nanCOMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population nanUNKNOWN
Supplementation With Altha-aminoacids and Systemiec Inflammatory Response in Long-distance Runners. nanUNKNOWN
Effects of Dietary Proteins on Hepatic Lipid Metabolism nanCOMPLETED
Postprandial Metabolism in Healthy Young Subjects nanCOMPLETED
Acute Fatty Acid Intervention Study (AFAST) nanCOMPLETED
Effects of Canola Oil on Vascular and Metabolic Parameters in Individuals With Metabolic Syndrome nanCOMPLETED
Validating Gulf War Illness Blood Biomarkers nanRECRUITING
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism nanCOMPLETED
Cardiovascular Risk Factors, Lipid Metabolism and Oxidative Stress nanUNKNOWN
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NOTUM binder may also engage these)

ProteinNameSimilarity
Q8R116 — 0.999 Q8R116 →
C5H5C4 — 0.967 C5H5C4 →
A0A0D3QS99 — 0.964 A0A0D3QS99 →
Q3UHN9 — 0.956 Q3UHN9 →
A0A0D3QS98 — 0.956 A0A0D3QS98 →
O12972 — 0.955 O12972 →
Q6NW40 — 0.955 Q6NW40 →
Q02353 — 0.954 Q02353 →
Q5U4X8 — 0.954 Q5U4X8 →
Q9H3R1 — 0.953 Q9H3R1 →
Q9NVE7 — 0.953 Q9NVE7 →
Q5R5F8 — 0.953 Q5R5F8 →
P52848 — 0.952 P52848 →
Q6ZRP7 — 0.952 Q6ZRP7 →
Q6ZQ11 — 0.951 Q6ZQ11 →
Q4R4U1 — 0.951 Q4R4U1 →
Q9EQW8 — 0.950 Q9EQW8 →
A6NDV4 — 0.950 A6NDV4 →
TRPM2 Transient receptor potential cation channel subfamily M member 2 0.950 landscape →
Q91YD4 — 0.950 Q91YD4 →
B1AWJ5 — 0.950 B1AWJ5 →
O97583 — 0.950 O97583 →
Q8R087 — 0.949 Q8R087 →
P52850 — 0.949 P52850 →
Q7TQ33 — 0.948 Q7TQ33 →
Q9EQH7 — 0.948 Q9EQH7 →
Q96RR1 — 0.948 Q96RR1 →
P16442 — 0.948 P16442 →
Q9GM01 — 0.948 Q9GM01 →
Q8CIW5 — 0.948 Q8CIW5 →